COMP <GO>
SPSC vs CLBT // EV/EBITDA & P/E VALUATION
SPS Commerce Inc. (NASDAQ) VS. Cellebrite DI Ltd. (NASDAQ) • 15-METRIC TALLY: SPSC 5
— CLBT 6
▲ EV/EBITDA & P/E VALUATION LEADER: SPSC
LAST: $85.78 (+0.22%) • MKT CAP: $3.09B
valuation
20.9x
LAST: $12.28 (+3.02%) • MKT CAP: $3.09B
valuation
38.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPSC VS. CLBT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPSC | CLBT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.20% | 84.20% | -15.00 | CLBT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.40% | 14.60% | -3.20 | CLBT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.9x | 38.1x | -17.20 | SPSC | /valuation <GO> |
| Free Cash Flow Yield | 4.93% | 5.19% | -0.26 | CLBT | /fcf-yield <GO> |
| Operating Margin | 15.70% | 14.00% | +1.70 | SPSC | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 16.50% | -4.10 | CLBT | /net-margins <GO> |
| Revenue Growth (YoY) | 17.80% | 18.60% | -0.80 | CLBT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.13 | 4.95 | +6.18 | SPSC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.6 | 58.1 | -13.52 | CLBT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.8x | 33.1x | -5.30 | SPSC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.09B | $3.09B | $1.6M | SPSC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPSC REV | CLBT REV | SPSC GROSS % | CLBT GROSS % | SPSC FCF | CLBT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $751.5M | $475.7M | 69.2% | 84.2% | $152.3M | $160.3M |
| FY 2024 | $637.8M | $401.2M | 67.0% | 84.4% | $137.4M | $123.6M |
| FY 2023 | $536.9M | $325.1M | — | — | $132.3M | $102.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPSC // BETA —
CLBT // BETA —